|
- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- MedEspera: International Medical Congress for Students and Young Doctors
- MedEspera 2024
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/28803
Title: | Substance use disorder in individuals with schizophrenia |
Authors: | Bivol Mădălina |
Issue Date: | 2024 |
Publisher: | Instituţia Publică Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” din Republica Moldova |
Citation: | Bivol Mădălina. Substance use disorder in individuals with schizophrenia. In: Abstract Book. MedEspera 2024. The 10th International Medical Congress for Students and Young Doctors. 24-27 April 2024, Chișinău, Republic of Moldova, p. 398. ISBN 978-9975-3544-2-4. |
Abstract: | Introduction. Schizophrenia can be defined as a mental disorder that affects a person’s thoughts, actions, expression of the emotions, perception of reality, and relations with other people. Schizophrenia is one of the top 15 leading causes of disability. The World Health Organization (WHO) reports that worldwide, one out of every 300 individuals is affected by this disorder, and its prevalence on a global scale varies between 0.3-0.7%. The critical age of onset and behavioral manifestation for schizophrenia occurs at the end of adolescence or early adulthood, and it is notably lower in substance users compared to patients without any form of abuse. Drug consumption among patients with schizophrenia varies, but cannabis, alcohol and cocaine remain among the most commonly used substances, significantly impacting symptoms and disease management. Aim of study. Schizophrenia and substance abuse commonly share overlapping risk factors, including genetic predisposition, environmental influences, and neurobiological vulnerability, contributing to their heightened co-occurrence. Their association is correlated with a higher frequency of relapses, extensive manifestations of positive symptoms, depression, cognitive impairments, less favorable outcomes, and ineffective responses to treatment. It is also notable that the age of onset for schizophrenia is significantly lower in drug users compared to patients without a history of abuse. The remarkable association between schizophrenia and substance abuse, especially among patients experiencing their first episode of the illness, is a significant and intriguing aspect in mental health research. Employing dual therapy, which integrates interventions addressing both mental health and substance dependency, is frequently crucial for ensuring a holistic and efficacious approach. Methods and materials. An advanced search was performed in the PubMed and Medline databases, taking into account relevant articles, published in the last 10 years. We used the following keywords and word combinations to search for: ”Substance abuse”, ”schizophrenia”, ”Substance use disorders”. Results. According to existing data in the specialized literature, the prevalence of substance use disorders (SUD) in individuals with schizophrenia is estimated to be between 20% and 65%, with variations across different studies. Patients with schizophrenia have a significantly higher risk of experiencing SUD compared to the general population. The relationship between SUD and schizophrenia is explained by four hypotheses, including the self-medication hypothesis, common vulnerability hypothesis, the theory of dysregulated dopaminergic reward system and the hypothesis of treatment side effects. However, the exact directionality of the relationship between substance use and schizophrenia remains unclear. Multiple studies suggest a high prevalence, approximately 35%, of substance abuse in the first episode of schizophrenia. The most commonly abused substances in schizophrenic patients were cannabis, followed by alcohol. Scientific research appears to indicate that a younger age of onset in the abuser group, male gender, lower education level, and the use of psychostimulants are factors associated with the onset of schizophrenia at an early stage of life, leading to a higher risk of dependence, increased severity of psychotic symptoms, and ultimately, a variety of poorer outcomes. Conclusion. In conclusion, the intricate relationship between schizophrenia and substance abuse, particularly in the context of the first episode, underscores the need for a comprehensive understanding and integrated therapeutic approaches. expression of the emotions, perception of reality, and relation s with other people. Schizophrenia is one of the top 15 leading causes of disability. The World Health Organi zation (WHO) reports that worldwide, one out of every 300 individuals is affected by this disorder, and its prevalence on a global scale varies between 0.3-0.7%. The critical age of onset and behavioral manifesta tion for schizophrenia occurs at the end of adolescence or early adulthood, and it is notably lower in substa nce users compared to patients without any form of abuse. Drug consumption among patients with schizophrenia varies, but cannabis, alcohol and cocaine remain among the most commonly used substances, significantl y impacting symptoms and disease management. Aim of study. Schizophrenia and substance abuse commonly share overlapping risk f actors, including genetic predisposition, environmental influences, and neurobiologica l vulnerability, contributing to their heightened co-occurrence. Their association is correlated wi th a higher frequency of relapses, extensive manifestations of positive symptoms, depression, cognitive impairment s, less favorable outcomes, and ineffective responses to treatment. It is also notable that the age of onset for schizophrenia is significantly lower in drug users compared to patients without a history of abuse. The remarkable association between schizophrenia and substance abuse, especially among patients expe riencing their first episode of the illness, is a significant and intriguing aspect in mental health res earch. Employing dual therapy, which integrates interventions addressing both mental health and substance depende ncy, is frequently crucial for ensuring a holistic and efficacious approach. Methods and materials. An advanced search was performed in the PubMed and Medline da tabases, taking into account relevant articles, published in the last 10 years. We used the following keywords and word combinations to search for: ”Substance abuse”, ”schizophrenia”, ” Substance use disorders”. Results. According to existing data in the specialized literature, the prevalence of substance use disorders (SUD) in individuals with schizophrenia is estimated to be between 20% and 65%, with variations across different studies. Patients with schizophrenia have a signific antly higher risk of experiencing SUD compared to the general population. The relationship between SUD and schizophrenia is explained by four hypotheses, including the self-medication hypothesis, common vulne rability hypothesis, the theory of dysregulated dopaminergic reward system and the hypothesis of tre atment side effects. However, the exact directionality of the relationship between substance use and schizophrenia remains unclear. Multiple studies suggest a high prevalence, approximately 35%, of substance abuse in t he first episode of schizophrenia. The most commonly abused substances in schizophrenic patients were cannabis, followed by alcohol. Scientific research appears to indicate that a younger a ge of onset in the abuser group, male gender, lower education level, and the use of psychostimulants are factors asso ciated with the onset of schizophrenia at an early stage of life, leading to a higher risk of depe ndence, increased severity of psychotic symptoms, and ultimately, a variety of poorer outcomes. Conclusion. In conclusion, the intricate relationship between schizophr enia and substance abuse, particularly in the context of the first episode, underscores the nee d for a comprehensive understanding and integrated therapeutic approaches. |
metadata.dc.relation.ispartof: | MedEspera 2024 |
URI: | https://ibn.idsi.md/collection_view/3104 http://repository.usmf.md/handle/20.500.12710/28803 |
ISBN: | 978-9975-3544-2-4 |
Appears in Collections: | MedEspera 2024
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|